Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetic and Immunological Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PHF11 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PHF11 Recombinant Protein (PHD Finger Domain / Full Length) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for SPR/BLI and biochemical screening. |
View PHF11 Products |
| Gene Delivery | PHF11 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and target engagement assays. |
View PHF11 Products |
| Benchmark Ab | Anti-PHF11 Recombinant Antibody High-affinity positive control antibody for Western Blot, IHC, and IP validation. |
View PHF11 Products |
| Validator | PHF11 siRNA Set Target-specific knockdown verification in human immune or tumor cell lines. |
View PHF11 Products |
| Related Target A | SETDB1 Histone methyltransferase that physically interacts with PHF11; critical for chromatin remodeling and gene silencing pathways. |
View SETDB1 Products |
| Related Target B | STAT6 Key transcription factor in Th2 cytokine signaling, synergizing with PHF11 in IgE synthesis regulation. |
View STAT6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PHD domain-specific binding accuracy | Truncated PHD-finger domain constructs available with verified sequence identity and >95% purity by SDS-PAGE. |
| High-throughput screening (HTS) compatibility | GST-tagged or His-tagged PHF11 proteins designed for seamless integration into AlphaLISA or TR-FRET assays. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and recombinant positive controls included in the portfolio. |
| Off-target profiling | Homolog screening panels (other PHD-finger family proteins) available for selectivity profiling. |
Live PHF11 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of PHF11 (Plant Homeodomain Finger Protein 11) represents an emerging frontier in both immunology and oncology. Historically recognized as a genetic modifier of IgE synthesis, asthma, and atopic dermatitis, recent studies highlight PHF11's broader role as an epigenetic reader and transcriptional regulator. The race for PHF11 therapeutics is intensifying, with major players shifting focus from traditional systemic immunosuppression to targeted small-molecule inhibitors of epigenetic reader domains. As first-generation epigenetic therapies reach the clinic, the next wave of R&D is targeting the specific protein-protein interactions (PPI) mediated by the PHF11 PHD finger to achieve tissue-specific immune modulation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | Atopic Dermatitis, Asthma, Epigenetic Cancers | Selectivity Assay (Need high-purity PHD domain vs. other PHD-finger proteins) |
| PROTAC / Degraders | Targeted Protein Degradation (TPD) Pioneers | Refractory Inflammatory Diseases, Solid Tumors | Ternary Complex Formation (Need highly stable, biotinylated or tagged PHF11) |
| RNA Therapeutics / siRNA | Gene Therapy Innovators | Severe Atopic Allergy, Hyper-IgE Syndromes | Target Knockdown Validation (Need validated siRNA and Lentivirus controls) |